Correction
After publication of this work [1], we noted that a figure reproduced from Lopez et al. [2], was revised in an erratum.
In Figure three (Fig. 1 here), the uppermost solid line represents placebo and the lower solid line (at 0.5 h), represents Ritalin LA® 20 mg capsule. In addition, labelling of the x-axis should read “0.5, 1, 2, 3, 4, 6, 8” hours.
Fig. 1.
ᅟ
Footnotes
David Coghill and Tobias Banaschewski are joint first authors.
Antonella Gagliano and Manfred Doepfner are joint last authors.
The online version of the original article can be found under doi:10.1186/1471-244X-13-237.
References
- 1.Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:237. doi: 10.1186/1471-244X-13-237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs. 2003;5:545–55. doi: 10.2165/00148581-200305080-00005. [DOI] [PubMed] [Google Scholar]